Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuro Panel Narrowly OKs Medtronic's Deep Brain Stim Device For Epilepsy

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's deep brain stimulation device designed to treat epilepsy gained the support of FDA's Neurological Devices Panel March 12 with a 7-5 vote in favor of PMA approval

You may also be interested in...



Global Device Approvals, Weekly Snapshot: April 23-29, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.

Medtronic's DBS approval delayed

PMA approval for Medtronic's DBS system for treatment of epilepsy may be delayed following a recent FDA request for additional data, which will require further clinical study. In March, FDA's Neurological Devices Panel recommended approval with conditions for the deep brain stimulation device, and the firm had predicted last November that it could receive PMA approval by this summer (1"The Gray Sheet" March 15, 2010). FDA's new data request will likely push out PMA approval by two to three years, JP Morgan analyst Michael Weinstein said in a Sept. 16 report. On Sept. 16, Medtronic announced it had received a CE mark for the DBS system to treat epilepsy; the firm will launch the device in Europe by the end of the year

Medtronic's DBS approval delayed

PMA approval for Medtronic's DBS system for treatment of epilepsy may be delayed following a recent FDA request for additional data, which will require further clinical study. In March, FDA's Neurological Devices Panel recommended approval with conditions for the deep brain stimulation device, and the firm had predicted last November that it could receive PMA approval by this summer (1"The Gray Sheet" March 15, 2010). FDA's new data request will likely push out PMA approval by two to three years, JP Morgan analyst Michael Weinstein said in a Sept. 16 report. On Sept. 16, Medtronic announced it had received a CE mark for the DBS system to treat epilepsy; the firm will launch the device in Europe by the end of the year

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel